Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study.

MLA

Någård, Mats, et al. “Adavosertib (AZD1775) Does Not Prolong the QTc Interval in Patients with Advanced Solid Tumors: A Phase I Open-Label Study.” Cancer Chemotherapy & Pharmacology, vol. 92, no. 2, Aug. 2023, pp. 141–50. EBSCOhost, https://doi.org/10.1007/s00280-023-04555-2.

APA

Någård, M., Ah-See, M.-L., Strauss, J., Wise-Draper, T., Safran, H. P., Nadeau, L., Edenfield, W. J., Lewis, L. D., Rekić, D., Dota, C., Ottesen, L. H., Li, Y., & Mugundu, G. M. (2023). Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study. Cancer Chemotherapy & Pharmacology, 92(2), 141–150. https://doi.org/10.1007/s00280-023-04555-2

Chicago

Någård, Mats, Mei-Lin Ah-See, James Strauss, Trisha Wise-Draper, Howard P. Safran, Laura Nadeau, William J. Edenfield, et al. 2023. “Adavosertib (AZD1775) Does Not Prolong the QTc Interval in Patients with Advanced Solid Tumors: A Phase I Open-Label Study.” Cancer Chemotherapy & Pharmacology 92 (2): 141–50. doi:10.1007/s00280-023-04555-2.